| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/13/2022 | — | Guggenheim | Downgrades | Buy → Neutral | |
| 09/09/2022 | 64.84% | Morgan Stanley | $2 → $1.5 | Maintains | Equal-Weight |
| 08/09/2022 | 9.89% | SVB Leerink | $2 → $1 | Maintains | Market Perform |
| 05/11/2022 | 119.78% | Morgan Stanley | $4 → $2 | Maintains | Equal-Weight |
| 05/11/2022 | 779.12% | HC Wainwright & Co. | $15 → $8 | Maintains | Buy |
| 05/10/2022 | 229.67% | SVB Leerink | $2 → $3 | Maintains | Market Perform |
| 04/11/2022 | 339.56% | Morgan Stanley | $15 → $4 | Maintains | Equal-Weight |
| 04/11/2022 | 449.45% | Guggenheim | $25 → $5 | Maintains | Buy |
| 04/11/2022 | 1548.35% | HC Wainwright & Co. | $40 → $15 | Maintains | Buy |
| 04/11/2022 | 229.67% | SVB Leerink | $5 → $3 | Maintains | Market Perform |
| 02/25/2022 | 449.45% | SVB Leerink | $14 → $5 | Maintains | Market Perform |
| 11/09/2021 | 1438.46% | SVB Leerink | $20 → $14 | Maintains | Market Perform |
| 05/18/2021 | 2647.25% | Morgan Stanley | $24 → $25 | Maintains | Equal-Weight |
| 04/19/2021 | 2537.36% | Morgan Stanley | $10 → $24 | Maintains | Equal-Weight |
| 03/15/2021 | 2097.8% | SVB Leerink | $4 → $20 | Maintains | Market Perform |
| 03/15/2021 | 4295.6% | HC Wainwright & Co. | $28 → $40 | Maintains | Buy |
| 02/23/2021 | 339.56% | SVB Leerink | $5 → $4 | Maintains | Market Perform |
| 01/19/2021 | 998.9% | Morgan Stanley | $5 → $10 | Maintains | Equal-Weight |
| 11/11/2020 | 449.45% | Morgan Stanley | $4 → $5 | Maintains | Equal-Weight |
| 03/13/2020 | 339.56% | Morgan Stanley | $15 → $4 | Downgrades | Overweight → Equal-Weight |
| 03/13/2020 | 2976.92% | HC Wainwright & Co. | $40 → $28 | Maintains | Buy |
| 11/15/2019 | 1878.02% | JP Morgan | $22 → $18 | Maintains | Overweight |
| 11/15/2019 | 1548.35% | Morgan Stanley | $17 → $15 | Maintains | Overweight |
| 09/10/2019 | 339.56% | Baird | → $4 | Initiates Coverage On | → Underperform |
| 08/29/2019 | 2317.58% | JP Morgan | $27 → $22 | Maintains | Overweight |
| 06/26/2019 | 4295.6% | HC Wainwright & Co. | → $40 | Initiates Coverage On | → Buy |
| 05/31/2019 | 2647.25% | Guggenheim | → $25 | Initiates Coverage On | → Buy |
| 12/19/2018 | 3636.26% | Morgan Stanley | $37 → $34 | Maintains | Overweight |
| 08/13/2018 | 3196.7% | Leerink Swann | → $30 | Initiates Coverage On | → Outperform |
| 08/13/2018 | — | JP Morgan | Initiates Coverage On | → Overweight | |
| 08/13/2018 | 3965.93% | Morgan Stanley | → $37 | Initiates Coverage On | → Overweight |
| 08/13/2018 | 4295.6% | Jefferies | → $40 | Initiates Coverage On | → Buy |
Rubius Therapeutics Questions & Answers
The latest price target for Rubius Therapeutics (NASDAQ: RUBY) was reported by Guggenheim on September 13, 2022. The analyst firm set a price target for $0.00 expecting RUBY to fall to within 12 months (a possible -100.00% downside). 12 analyst firms have reported ratings in the last year.
The latest analyst rating for Rubius Therapeutics (NASDAQ: RUBY) was provided by Guggenheim, and Rubius Therapeutics downgraded their neutral rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Rubius Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Rubius Therapeutics was filed on September 13, 2022 so you should expect the next rating to be made available sometime around September 13, 2023.
While ratings are subjective and will change, the latest Rubius Therapeutics (RUBY) rating was a downgraded with a price target of $0.00 to $0.00. The current price Rubius Therapeutics (RUBY) is trading at is $0.91, which is out of the analyst's predicted range.
